Similarly, in prostate cancer, overexpression of PPARγ promotes Akt3 activity, inhibits nuclear output protein CRM1, and enhances nuclear retention of PPARγ coactivator 1α (PGC1α). Here, PPARG is linked to Familial prostate cancer.